Amundi
BIO icon

Amundi’s Bio-Rad Laboratories Class A BIO Stock Holding History

Amundi’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.42M Sell
15,057
-23,721
-61% -$6.73M ﹤0.01% 1036
2026
Q1 		$10.8M Buy
38,778
+36,697
+1,763% +$10.6M ﹤0.01% 868
2025
Q4 		$631K Buy
2,081
+31
+2% +$9.67K ﹤0.01% 1394
2025
Q3 		$634K Buy
2,050
+174
+9% +$47.4K ﹤0.01% 1264
2025
Q2 		$470K Sell
1,876
-21,460
-92% -$5.07M ﹤0.01% 1390
2025
Q1 		$5.48M Buy
23,336
+3,294
+16% +$991K ﹤0.01% 934
2024
Q4 		$6.9M Sell
20,042
-16,596
-45% -$5.63M ﹤0.01% 928
2024
Q3 		$12.4M Sell
36,638
-8,099
-18% -$2.57M ﹤0.01% 801
2024
Q2 		$12.1M Buy
44,737
+234
+0.5% +$68.1K ﹤0.01% 796
2024
Q1 		$12.5M Sell
44,503
-150,139
-77% -$49.4M 0.01% 789
2023
Q4 		$61.9M Buy
194,642
+111,698
+135% +$35M 0.03% 486
2023
Q3 		$28.6M Buy
82,944
+25,525
+44% +$9.85M 0.01% 635
2023
Q2 		$21.7M Sell
57,419
-41,944
-42% -$17.1M 0.01% 682
2023
Q1 		$46.1M Sell
99,363
-152,688
-61% -$71.5M 0.02% 520
2022
Q4 		$116M Buy
252,051
+78,235
+45% +$31.6M 0.06% 313
2022
Q3 		$79.3M Buy
173,816
+145,942
+524% +$72.8M 0.05% 393
2022
Q2 		$13.6M Sell
27,874
-9,063
-25% -$4.72M 0.01% 706
2022
Q1 		$22M Buy
36,937
+1,191
+3% +$718K 0.01% 634
2021
Q4 		$22.8M Buy
35,746
+30
+0.1% +$22.5K 0.01% 653
2021
Q3 		$26.6M Buy
35,716
+763
+2% +$572K 0.02% 610
2021
Q2 		$22.5M Buy
+34,953
New +$21.3M 0.02% 645

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Amundi's BIO Position: Q2 2026 in Review

Amundi reduced its Bio-Rad Laboratories Class A (BIO) stake by 61% in Q2 2026, selling an estimated $6.73M and leaving 15,057 shares worth $4.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1036.

Amundi first reported a position in BIO in Q2 2021 and has held it in 21 quarters since. The position peaked at $116M in Q4 2022. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Amundi held 15,057 shares of Bio-Rad Laboratories Class A worth $4.42M as of Q2 2026.
  • Amundi sold 23,721 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $6.73M.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1036 holding.
  • Amundi first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and has held it in 21 quarters since.
  • Amundi's Bio-Rad Laboratories Class A position peaked at $116M in Q4 2022.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.